Mitochondrial care in acute myocardial infarction

European Heart Journal

Volumn 36, Issue 2, 2015, Pages 77-79

  BØtker, Hans Erik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN D; CYCLOSPORIN A; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; REACTIVE OXYGEN METABOLITE; CARDIOTONIC AGENT; OXIME; SECOSTEROID;

ACUTE HEART INFARCTION; CARDIOVASCULAR MAGNETIC RESONANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; MITOCHONDRION; NONHUMAN; OUTER MEMBRANE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; FEMALE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROCEDURES;

ANGIOPLASTY, BALLOON; CARDIOTONIC AGENTS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OXIMES; SECOSTEROIDS;

EID: 84925329275     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu380     Document Type: Review

References (15)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. NEngl J Med 2007;357(11): 1121-1135
2. Terkelsen CJ, Kaltoft AK, Norgaard BL, Bottcher M, Lassen JF, Clausen K, Nielsen SS, Thuesen L, Nielsen TT, Botker HE, Andersen HR. ST changes before and during primary percutaneous coronary intervention predict final infarct size in patients with ST elevation myocardial infarction. J Electrocardiol 2009;42(1):64-72
3. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R, Working Group of Cellular Biology of Heart of European Society of C. Postconditioning and protection from reperfusion injury: where do we stand?. Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010;87(3):406-423
4. Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, De Caralt TM, Betriu A, Masotti M. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 2012; 33(1):103-112
5. Limalanathan S, Andersen GO, Klow NE, Abdelnoor M, Hoffmann P, Eritsland J. Effect of ischaemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc 2014;3(2):e000679
6. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sorensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375(9716):727-734
7. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, Panagopoulou V, Tsarouchas K, Vavetsi S, Pyrgakis V, Deftereos S. Cardioprotective role of remote ischaemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv 2010;3(1):49-55
8. Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, Pedersen L, Sorensen HT, Botker HE, Investigators C. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 2014;35(3):168-175
9. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008;118(19):1915-1919
10. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307(Pt 1):93-98
11. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359(5):473-481
12. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM. Metformin protects the ischaemic heart by the Aktmediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008;103(3):274-284
13. Hausenloy DJ, Erik Botker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M. Translating cardioprotection for patient benefit: position paper from theWorking Group of Cellular Biologyof the Heart of the European Society of Cardiology. Cardiovasc Res 2013;98(1):7-27
14. Schaller S, Paradis S, Ngoh GA, Assaly R, Buisson B, Drouot C, Ostuni MA, Lacapere JJ, Bassissi F, Bordet T, Berdeaux A, Jones SP, Morin D, Pruss RM. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther 2010;333(3):696-706
15. Le Lamer S, Paradis S, Rahmouni H, Chaimbault C, Michaud M, Culcasi M, Afxantidis J, Latreille M, Berna P, Berdeaux A, Pietri S, Morin D, Donazzolo Y, Abitbol JL, Pruss RM, Schaller S. Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial. J Transl Med 2014;12:38